Immune responses to myxoma virus
- PMID: 12081009
- DOI: 10.1089/08828240260066198
Immune responses to myxoma virus
Abstract
Myxoma virus causes the systemic disease myxomatosis in the European rabbit (Oryctolagus cuniculus). Originating in the South American rabbit Sylvilagus brasiliensis, where it causes a relatively localized fibroma, myxoma virus is a classic example of a virus that has jumped species to produce an exotic disease and then coevolved with its new host. Like other poxviruses, myxoma virus encodes multiple proteins capable of downregulating the host innate and acquired immune responses. Other virus-encoded proteins enable replication in host lymphocytes and monocytes, for example, by inhibiting apoptosis. Detailed studies on these proteins have demonstrated novel methods of interactions with the host immune system and added substantially to the understanding of the interaction of large DNA viruses with their hosts. Despite the increasingly detailed molecular knowledge of myxoma virus, relatively little is known about the dynamics of the interaction of the virus with the integrated host-immune system during infection and, in particular, about the evolution of resistance to the virus in wild rabbits or the species barrier. This review will focus on the detailed molecular studies that have been done with myxoma virus and discuss the more limited knowledge of the pathogenesis of myxoma virus in rabbits and the ways that the consolidated immune responses may determine genetic resistance to myxomatosis.
Similar articles
-
Myxoma virus M-T7, a secreted homolog of the interferon-gamma receptor, is a critical virulence factor for the development of myxomatosis in European rabbits.Virology. 1996 Jan 1;215(1):17-30. doi: 10.1006/viro.1996.0003. Virology. 1996. PMID: 8553583
-
Myxoma virus in the European rabbit: interactions between the virus and its susceptible host.Vet Res. 2007 Mar-Apr;38(2):299-318. doi: 10.1051/vetres:2006054. Epub 2007 Feb 13. Vet Res. 2007. PMID: 17296158 Review.
-
Myxomatosis in Australia and Europe: a model for emerging infectious diseases.Antiviral Res. 2012 Mar;93(3):387-415. doi: 10.1016/j.antiviral.2012.01.009. Epub 2012 Feb 8. Antiviral Res. 2012. PMID: 22333483 Review.
-
A pox on thee! Manipulation of the host immune system by myxoma virus and implications for viral-host co-adaptation.Virus Res. 2002 Sep;88(1-2):17-33. doi: 10.1016/s0168-1702(02)00118-1. Virus Res. 2002. PMID: 12297325 Review.
-
Myxoma virus in rabbits.Rev Sci Tech. 1998 Apr;17(1):256-68. doi: 10.20506/rst.17.1.1081. Rev Sci Tech. 1998. PMID: 9638815 Review.
Cited by
-
Oncolytic Myxoma virus infects and damages the tegument of the human parasitic flatworm Schistosoma mansoni.Exp Parasitol. 2022 Aug;239:108263. doi: 10.1016/j.exppara.2022.108263. Epub 2022 May 19. Exp Parasitol. 2022. PMID: 35598646 Free PMC article.
-
Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta.Cytokine. 2009 Sep;47(3):199-205. doi: 10.1016/j.cyto.2009.06.006. Epub 2009 Jul 28. Cytokine. 2009. PMID: 19640730 Free PMC article.
-
Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.Cancer J. 2012 Jan-Feb;18(1):69-81. doi: 10.1097/PPO.0b013e31824671c9. Cancer J. 2012. PMID: 22290260 Free PMC article. Review.
-
Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor.Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4640-5. doi: 10.1073/pnas.0509341103. Epub 2006 Mar 14. Proc Natl Acad Sci U S A. 2006. PMID: 16537421 Free PMC article.
-
Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.Clin Cancer Res. 2008 Feb 15;14(4):1218-27. doi: 10.1158/1078-0432.CCR-07-1330. Clin Cancer Res. 2008. PMID: 18281557 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources